Antibodies ; immunology ; Graft Rejection ; drug therapy ; immunology ; prevention & control ; Graft Survival ; immunology ; Humans

Chronic Disease ; Graft Rejection ; therapy ; Humans ; Integrative Medicine ; Kidney Diseases ; etiology ; therapy ; Kidney Transplantation ; adverse effects

OBJECTIVE: To determine the effect of transient withdrawal of immunosuppressive agents during the treatment of pulmonary infection on long-term survival of patients and graft s. METHODS: A total of 104 patients with post-transplant pulmonary infection were enrolled in this study. These patients received renal transplantation in Center for Organ Transplantation, Xiangya Hospital, Central South University, during December 2005 and August 2014. Among them, 50 patients stopped immunosuppressive agents during the treatment of infection. These patients served as stopping drug (SD) group, whereas the remaining patients who served as a control group did not stop immunosuppressive drugs. The five-year cumulative patient survival, graft survival, and laboratory results were compared between the 2 groups. RESULTS: The five-year cumulative patient survival rates in the SD group were significantly lower than those in the control group [(69.8 ± 7.0)% vs (94.2 ± 3.2)%, P=0.001]. There was no significant difference in the allograft survival rates between the 2 groups [(81.7 ± 6.6)% vs (90.9 ± 4.3)%, P=0.113]. In patients who survived from pulmonary infection, there was no significant difference in long-term survival rates between the 2 groups (P=0.979). CONCLUSION Pulmonary infection impacts allograft survival after patients underwent renal transplantation. Transient stopping immunosuppressive agents during the treatment of infection is a safe and necessary treatment strategy for patients with serious post-transplant pulmonary infection.
Graft Rejection ; Graft Survival ; Humans ; Immunosuppressive Agents ; administration & dosage ; Kidney Transplantation ; Lung Diseases ; therapy ; Postoperative Complications ; Survival Rate ; Transplantation, Homologous

Kaposi's sarcoma is an unusual neoplasm that has proved to be an enigma in many ways since its original description by Kaposi in 1872. Of the several different type of Kaposi's sarcoma, iatrogenically immunosuppressed patients predisposed to Kaposi's sarcoma are usually either transplant recipients or patients receiving immunosuppressive therapy. We report a case of recurrent Kaposi's sarcoma in a 56 year old male, which has occurred during the cyclosporine therapy of kidney transplantation. Cyclosporine was discontinued and chemotherapy began and the resolution of Kaposi's sarcoma has been obtained. Cyclosporine maintenance therapy was started again for the prevention of graft rejection. But 1 year later, Kaposi's sarcoma recurred probably due to re-use of cyclosporine.
Cyclosporine* ; Drug Therapy ; Graft Rejection ; Humans ; Kidney Transplantation* ; Kidney* ; Male ; Middle Aged ; Sarcoma, Kaposi* ; Transplantation

OBJECTIVETo explore the promoting effects of cograft of auto-microskin and allo-dermal matrix on burn wound healing.

METHODSForty-six patches of full skin loss wounds were made in the backs of 6 small white swines. Auto-microskin and meshed acellular allo-dermal matrix were simultaneously prepared. The 46 wounds were averagely divided into test (T) and control (C) groups. The wounds in T group were covered with auto-microskin and allo-dermal matrix (1:4) and split-thick allo-porcine skin. While the wounds in C group were grafted with autoskin and allo-dermal matrix.

RESULTSThe skin survival rate exhibited no difference between C and T groups (P > 0.05). There was similar histological exhibition in the two groups after skin grafting. The structure of collagen fibres appeared integrated, clear with regular arrangement and steady diameter at 8 - 20 post-operative weeks. Simultaneously, it was revealed by histological examination that normal vascular structure could be identified in the grafted skin and that inflammatory reaction ameliorated gradually and that epithelium combined well with dermis. It was also found that the epidermal papillar across the basement membrane fixed well to allo-dermis. The skin appeared smooth, elastic and functioned well at 5 months after skin grafting.

CONCLUSIONThe grafted skin survived well after the cograft of auto-microskin and allo-dermal matrix, which might be ideal covering material for the major deep burn wound healing.

Animals ; Burns ; therapy ; Disease Models, Animal ; Female ; Graft Rejection ; Male ; Skin Transplantation ; Skin, Artificial ; Swine

One of the major obstacle for hematopoietic stem cell transplantation (HSCT) to treat patients with beta-thalassemia is graft rejection (GR). The proportion of donor-derived cells continually declined in mixed chimerism (MC), finally leading to graft failure. Monitoring chimerism after transplant consecutively can early find unstable mixed chimerism and rejection, which provide the basis for donor lymphocyte infusion (DLI); for imminent risk of graft rejection, escalating doses of DLI is a feasible method for converting unstable MC towards stable MC or full donor chimerism. This review focuses on advancement of chimerism monitoring and DLI after HSCT for patients with β-thalassemia major.
Graft Rejection ; etiology ; Humans ; Lymphocyte Transfusion ; Thalassemia ; therapy ; Tissue Donors ; Transplantation Chimera

OBJECTIVETo investigate the etiology and therapy of delayed graft function (DGF) recovery in renal transplant recipients.

METHODSThe clinical data were retrospectively analyzed in 15 renal recipients with DGF. All the 15 patients received hemodialysis along with pulse treatment against acute rejection (AR), or immunosuppressant adjustment, or in situ retransplantation after the resection of the original transplanted kidney according to different etiological factors.

RESULTSAmong the 15 patients, 8 developed AR, 5 showed acute renal tubular necrosis (ATN), 1 had grafting-associated renal vein embolism and 1 had acute cyclosporine nephrotoxication. The renal function recovered within 10 to 35 days after transplantation without complication during the follow-up period (0.5-3.0 years).

CONCLUSIONDGF is a common complication after kidney transplantation mainly due to the occurrence of AR and ATN. Good prognosis is expected if etiology-oriented therapy is performed properly and promptly.

Adult ; Delayed Graft Function ; physiopathology ; therapy ; Female ; Graft Rejection ; physiopathology ; therapy ; Graft Survival ; Humans ; Immunosuppressive Agents ; therapeutic use ; Kidney Transplantation ; Male ; Recovery of Function ; Renal Dialysis ; Retrospective Studies

Biliary Tract Diseases ; etiology ; surgery ; therapy ; Blood Loss, Surgical ; prevention & control ; Graft Rejection ; etiology ; therapy ; Humans ; Liver Transplantation ; adverse effects

Adult ; Graft Rejection ; drug therapy ; Humans ; Immunosuppressive Agents ; therapeutic use ; Liver Transplantation ; Male ; Middle Aged ; Muromonab-CD3 ; therapeutic use

In the past 50 years, organ transplantation has developed from an improbable laboratory exercise to a major therapeutic success. The surgical problems of organ grafting have, for the most part, been solved. Rejection of grafts is now partially understood and usually controllable by powerful immunosuppressive drugs. A steady improvement in patient outcome, especially following the introduction of cyclosporin as an immunosuppressive agent has resulted in a worldwide shortage of organs for transplantation. This has provoked serious ethical dilemmas in every country. These matters are summarised in the following text.
Biomedical Research ; Cyclosporine ; pharmacology ; Graft Rejection ; drug therapy ; prevention & control ; Humans ; Immunosuppression ; Immunosuppressive Agents ; pharmacology ; Transplants ; ethics